Reverse Medical® Corporation has announced CE Mark approval for its BARREL® Vascular Reconstruction Device (VRD) and the first European clinical case. The BARREL® Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.
Californian endovascular device specialist Reverse Medical Corporation develops what it calls a technology driven pipeline of innovative, state-of-the-art endovascular treatments for a broad spectrum of peripheral and neurovascular disorders and diseases. Its Barrel device, as the name suggests is a barrel shaped stent that is intended to provide support for bifurcation and lateral wall aneurysms in intracranial vessels, allowing the occlusion of the aneurysm and retention of an embolic device such as a coil within the aneurysm body.
“Our first experience with the BARREL VRD in a wide-neck bifurcation intracranial aneurysm was impressive. The device tracked easily through tortuous anatomy, had excellent angiographic visibility, was easily and completely re-sheathable, and deployed very nicely. The device required no radial orientation maneuvers for accurate placement, providing a single device alternative to surgery, or to technically challenging ‘X-Y’ stenting for these complex bifurcation aneurysms,” stated Michel Piotin, MD, PhD, Director, Department of Interventional Neuroradiology, Fondation Rothschild Hospital, Paris, France. Rafael Blanc, MD added, “I expect the BARREL to become an important tool in our practice.”
Reverse Medical President and CEO Jeffrey Valko commented, “The BARREL VRD represents our ongoing commitment as a neuro endovascular technology innovation company. We plan to expand our clinical experience with the BARREL technology, and begin commercialization in Europe through a network of expert distributors by mid 2014. The BARREL design is simple and elegant, essentially reducing the neck size of wide-neck bifurcation aneurysms, enabling traditional coil embolization, a craft already mastered by the Neuro Interventionalist.”
Source: Reverse Medical, Inc., Business Wire